The Full Plate Problem: Cannabis, CBD and the GLP-1 Makeover of British Appetite
Photo: elsaolofsson, CC BY 2.0, via Wikimedia Commons
Britain has always had a complicated relationship with appetite. We celebrate a Sunday roast, panic about ultra-processed food, and queue for a drug that makes dinner feel optional. In 2026, GLP-1 medications such as semaglutide and tirzepatide, sold as Ozempic, Wegovy and Mounjaro, have moved from diabetes treatment into the mainstream of weight-loss culture. The language has shifted too: 'food noise', 'quiet appetite', 'protein-first'. It is a whole new diet grammar.
Into that slipstream has stepped the cannabinoid industry. CBD brands are whispering about metabolism. Cannabis advocates are talking about appetite regulation. Influencers are asking whether a dropper of CBD can do what a weekly injection does. Most of this is not evidence. Some of it is not legal. A little of it is interesting. The question is whether cannabis and CBD have a credible role in the GLP-1 era, or whether they are just chasing the trend.
The nouvelle diet culture
GLP-1 drugs work by mimicking a gut hormone that slows gastric emptying and signals fullness to the brain. They have been hailed as a breakthrough and criticised as a quick fix. In the UK, NHS rollout has been phased, private clinics have boomed, and social media has turned the injection pen into a status symbol. The cultural effect is bigger than the clinical one: appetite itself has become a project.
That is fertile ground for wellness marketing. If appetite is a problem to be solved, every supplement wants to be part of the solution. CBD has an advantage here because it already has a reputation for calm. A brand can imply that a few drops will settle cravings without ever making a medical claim. It is soft-focus wellness, not hard science.
What the evidence actually says
Cannabis and appetite have a long, well-documented relationship. THC is an appetite stimulant. That is why medical cannabinoids have been used for nausea and appetite loss in specific conditions, and why the 'munchies' are a cultural cliché. But appetite stimulation is not appetite suppression. The idea that cannabis helps you eat less is mostly a misunderstanding of what the plant does.
CBD is a different molecule with a different marketing story. Preclinical studies have looked at CBD and the endocannabinoid system, inflammation, stress and metabolism. Some small human studies have looked at CBD and anxiety, sleep or craving. But there is no robust body of evidence that CBD causes clinically meaningful weight loss, suppresses appetite in the way GLP-1 drugs do, or resets metabolism. The claims are ahead of the science.
Medical cannabis is not a weight-loss treatment either. Licensed cannabinoid medicines are used for specific symptoms, not for general slimming. In the UK, unlicensed medical cannabis can be prescribed by specialist clinics for certain conditions, but 'appetite regulation' in the GLP-1 sense is not a standard indication. Anyone selling cannabis as a diet aid is either confused or hoping you are.
The UK rulebook
UK health claims law is stricter than the wellness aisle suggests. CBD food products are regulated as novel foods, and health claims must be authorised. Brands cannot say CBD treats obesity, suppresses appetite or replaces medication. The Advertising Standards Authority and the Medicines and Healthcare products Regulatory Agency have been clear that medicinal claims turn a supplement into a medicine. That does not stop influencers from hinting.
Patients should also be careful with interactions. GLP-1 drugs can slow gastric emptying and affect how other substances are absorbed. Cannabis can affect blood pressure, heart rate and coordination. Combining them is not a wellness experiment to run alone. If you are prescribed either, talk to your clinician. The internet is not a pharmacist.
The counterculture problem
There is an irony here. Counterculture has often treated appetite as something to be expanded, not suppressed. Food is pleasure. Cannabis is a social lubricant. The munchies are part of the folklore. The GLP-1 era offers the opposite fantasy: appetite as a switch to be turned down. Cannabis and CBD are being pulled into a culture war they did not start.
That is why the industry needs to be honest. Cannabis is not a skinny jab. CBD is not a metabolic reset. If brands want to be part of the conversation, they should talk about sleep, stress, movement and the messy business of eating well. They should fund real research rather than borrow the language of obesity medicine. And they should stop pretending that a dropper is a prescription.
A more honest appetite
The GLP-1 revolution has exposed how moralised appetite still is. We praise restraint and shame hunger. We celebrate a drug that makes food boring. Cannabis culture has its own blind spots, but it has at least kept a place for pleasure. The useful question is not whether CBD can replace Ozempic. It is whether cannabinoids can help people relax around food without turning appetite into another performance.
Until the evidence catches up, the honest answer is: probably not in the way the adverts imply. CBD may have a role in stress and sleep. Cannabis may help some patients with nausea or appetite loss. Neither is a weight-loss cure. In 2026, the smartest thing the cannabinoid sector can do is stop chasing the skinny jab and start telling the truth about what it actually does.
